Updated Outcomes of Sacituzumab Govitecan in Resistant Advanced Urothelial Carcinoma

1. The objective response rate was 28% with a complete response of 5.6% and a partial response of 23%. 2. Treatment-related adverse events grade ≥3 occurred in 65%, most commonly included neutropenia, leukopenia, and anemia. Evidence Rating Level: 2 (Good) Study Rundown: Treatment of advanced urothelial carcinoma remains challenging, with traditional chemotherapy showing limited efficacy. […]

The post Updated Outcomes of Sacituzumab Govitecan in Resistant Advanced Urothelial Carcinoma first appeared on 2 Minute Medicine.